证券代码：300204 证券简称：舒泰神 公告编号：2025-074 舒泰神（北京）生物制药股份有限公司 第六届董事会第十次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 舒泰神（北京）生物制药股份有限公司（以下简称"舒泰神"或"公司"） 第六届董事会第十次会议（以下简称"本次会议"）通知以电话、电子邮件等相结 合的方式于 2025 年 10 月 22 日发出，本次会议于 2025 年 10 月 28 日上午 09:00 在北京经济技术开发区经海二路 36 号公司会议室，以现场结合通讯方式召开。 本次会议应出席董事 9 名，实际出席董事 9 名，现场表决的董事 8 名，通讯表决 的董事 1 名。公司高级管理人员列席了会议。本次会议的召集与召开符合《中华 人民共和国公司法》（以下简称"《公司法》"）和《舒泰神（北京）生物制药股份 有限公司章程》（以下简称"《公司章程》"）的有关规定。 本次会议由董事长周志文先生召集和主持，与会董事经过充分讨论和认真审 议，一致同意并通过了如下决议： 一、审议通过《舒泰神（北京）生物制药股份有限公司 2025 年第三 ...

Financial Performance - Revenue for Q3 2025 was ¥54,941,098.61, a decrease of 30.10% compared to the same period last year[4] - Net profit attributable to shareholders was -¥6,053,967.38, a decline of 1.89% year-over-year[4] - The company reported a net cash flow from operating activities of -¥107,047,029.72, a decrease of 332.81% year-to-date[4] - Operating income decreased by ¥80,449,514.04, a decline of 30.82% attributed to reduced product sales[10] - Total operating revenue for the period was ¥180,538,395.51, a decrease of 30.8% compared to ¥260,987,909.55 in the previous period[34] - The net profit for the current period is -37,879,165.05, compared to -9,364,956.52 in the previous period, indicating a significant increase in losses[35] - Operating profit for the current period is -37,392,767.69, compared to -8,614,783.75 in the previous period, reflecting a worsening operational performance[35] - Total comprehensive income for the current period is -53,467,389.71, compared to 16,012,131.45 in the previous period, showing a substantial decline[36] - Cash flow from operating activities shows a net outflow of -107,047,029.72, compared to -24,733,298.84 in the previous period, indicating increased cash burn[38] Assets and Liabilities - Total assets increased to ¥1,263,925,202.35, reflecting a growth of 9.94% from the end of the previous year[5] - Total assets reached ¥1,263,925,202.35, up from ¥1,149,607,757.17, reflecting a growth of 9.9%[32] - Total liabilities increased to ¥404,224,404.94 from ¥232,846,415.32, a rise of 73.3%[32] - The company's total equity decreased to ¥859,700,797.41 from ¥916,761,341.85, a decline of 6.2%[32] Cash and Cash Equivalents - Cash and cash equivalents increased by ¥104,087,711.75, a rise of 193.07% due to new investments received[9] - Cash and cash equivalents increased to ¥157,998,891.79 from ¥53,911,180.04, representing a growth of 192.5%[30] - Cash and cash equivalents at the end of the period amount to 157,410,459.27, up from 42,731,525.34 in the previous period, reflecting improved liquidity[38] Accounts Receivable and Inventory - Accounts receivable increased by ¥11,722,383.16, up 8,071.18% primarily due to reduced bank acceptance bill payments[9] - Accounts receivable decreased to ¥33,804,624.73 from ¥38,928,239.79, a decline of 13.5%[30] - Inventory rose to ¥30,096,329.85 from ¥22,181,013.09, an increase of 35.9%[31] Expenses - Financial expenses surged by ¥4,721,576.68, an increase of 11,906.93% due to the recognition of financial liabilities related to share repurchase obligations[10] - Research and development expenses for the same period were 82.60 million yuan, down 24.99% from 110.13 million yuan in 2024[17] - Research and development expenses for the current period are 58,104,013.78, down from 77,690,259.04 in the previous period, suggesting a reduction in investment in innovation[35] - Sales expenses decreased to 89,004,469.80 from 114,566,444.96, indicating cost-cutting measures in sales operations[35] Tax and Other Income - Income tax expenses increased by CNY 79,212.36, a growth of 11,527.33% year-over-year, primarily due to accelerated depreciation of fixed assets leading to deferred income tax[11] - Other comprehensive income after tax changed from CNY 25,377,087.97 in the same period last year to CNY -15,588,224.66 this period, a change of CNY -40,965,312.63, representing a 161.43% change, mainly due to fair value changes of other equity instruments[11] - Cash received from sales of goods and services decreased by CNY 102,998,067.71, a decline of 38.75% year-over-year, primarily due to reduced product sales[11] - Cash received from tax refunds decreased by CNY 1,574,494.77, a decline of 89.44% year-over-year, mainly due to last year's receipt of tax refunds[11] - Cash received from other operating activities decreased by CNY 2,254,077.84, a decline of 42.93% year-over-year, primarily due to reduced cash flow from operating activities[11] - Cash received from investment income decreased by CNY 474,528.17, a decline of 93.42% year-over-year, mainly due to reduced income from other equity investments[11] - Cash received from the disposal of fixed assets increased by CNY 1,643,966.32, an increase of 1,007.76% year-over-year, primarily due to increased disposals of fixed assets[11] - Cash received from investments increased from CNY 0 to CNY 133,333,300.00, primarily due to investments received from Wuxi Jinyi Yuanli Equity Investment Partnership[11] - Cash received from borrowings increased from CNY 0 to CNY 41,644,342.43, primarily due to bank loans received this period[11] - Cash received from other financing activities increased by CNY 50,340,840.00, an increase of 308.35% year-over-year, mainly due to the disposal of partial subsidiary equity without losing control[11] Clinical Trials and Product Development - The STSA-1002 injection for acute respiratory distress syndrome showed preliminary efficacy with a 28-day all-cause mortality rate of 26.67% in the low-dose group, compared to 40.00% in the control group[22] - The BDB-001 injection for ANCA-associated vasculitis demonstrated a 12-week partial remission rate of 76.5% in the high-dose group, comparable to the standard treatment group[23] - The overall incidence of serious adverse events for BDB-001 was 24.7%, with the lowest rate in the low-dose group at 6.3%[23] - The company plans to advance the Phase III clinical trial for BDB-001 based on current data indicating significant clinical benefits[23] - The STSP-0902 eye drops showed good safety and tolerability in healthy subjects, supporting further clinical trials in patients with neurotrophic keratitis[24] Corporate Governance and Plans - The company announced a board meeting to elect a non-independent director, maintaining the number of independent directors at three[25] - The company approved a plan for a targeted stock issuance to specific investors during the board meeting held on September 8, 2025[25] - The company announced plans for a private placement of shares, pending approval from regulatory authorities[26] - The election of Mr. Zheng Hong as the employee representative director was confirmed, ensuring compliance with legal requirements[27] Audit and Reporting - The company has not undergone an audit for the third quarter financial report[39]

Core Viewpoint - Shuyou Shen (300204) plans to issue shares to specific investors to raise up to 1.253 billion yuan for innovative drug research and working capital, following approval from the board and shareholders [3][5]. Group 1: Financial Performance - As of December 31, 2024, the company's total consolidated assets amounted to 1,149.61 million yuan, with total liabilities of 232.85 million yuan and equity attributable to shareholders of 929.23 million yuan [2]. - For the fiscal year 2024, the company reported a consolidated revenue of 324.82 million yuan and a net loss of 147.73 million yuan, with a negative cash flow from operating activities of 63.68 million yuan [2]. - The company has experienced continuous net losses over the past three years, with a net loss of 24.64 million yuan in the first half of 2025 [4]. Group 2: Stock Issuance Details - The planned share issuance will not exceed 143,331,766 shares, representing 30% of the total share capital prior to the issuance, with a minimum issuance price set at 80% of the average trading price over the previous 20 trading days [3][5]. - The funds raised will be allocated as follows: 883 million yuan for clinical research and registration of innovative drugs (BDB-001, STSA-1002, STSP-0902) and 370 million yuan for working capital [5]. - The issuance is subject to approval from the Shenzhen Stock Exchange and registration with the China Securities Regulatory Commission [4][5]. Group 3: Market Activity - On October 27, 2025, Shuyou Shen's stock closed at 34.13 yuan, with a trading volume of 342,800 shares and a turnover of 1.189 billion yuan [1]. - The net outflow of funds from major investors on the same day was 57.71 million yuan, while retail investors saw a net inflow of 95.75 million yuan [2][4].

Core Points - Shuyou Shen (300204) reported a closing price of 34.13 yuan on October 27, 2025, with a market capitalization of 16.306 billion yuan, reflecting a 0.47% increase from the previous trading day [1] - The company announced a plan to issue shares to specific investors, aiming to raise no more than 1.253 billion yuan for innovative drug research and to supplement working capital [1] - The share issuance will not exceed 30% of the total share capital prior to issuance, amounting to 143,331,766 shares, and has been approved by the board and shareholders, pending review by the Shenzhen Stock Exchange and registration with the CSRC [1] Financial Details - The funds raised will allocate 883 million yuan for clinical research and registration of innovative drugs BDB-001, STSA-1002, and STSP-0902, while 370 million yuan will be used to supplement working capital [1] - The issuance will not result in a change of control for the company and does not constitute a major asset restructuring [1] Risk Factors - The company has indicated potential risks including performance losses and the possibility that fundraising projects may not meet expectations [1]

Group 1 - Shuyou Shen plans to raise no more than 1.253 billion yuan through a private placement to support innovative drug research and supplement working capital [1] - The issuance will involve no more than 143 million shares, with the price set at no less than 80% of the average trading price over the previous 20 trading days [1] Group 2 - WuXi AppTec reported a 84.84% year-on-year increase in net profit for the first three quarters, reaching 12.076 billion yuan, driven by a focus on CRDMO business and gains from selling shares in WuXi XDC Cayman Inc. [2] - The company achieved a revenue of 32.857 billion yuan, marking an 18.61% year-on-year growth [2] Group 3 - Wanfu Bio's net profit for the first three quarters decreased by nearly 70%, with a revenue of 1.69 billion yuan, down 22.52% year-on-year [3] - The third quarter revenue was 445 million yuan, a decline of 26.66% [3] Group 4 - Jincheng Pharmaceutical reported a 79.1% year-on-year decrease in net profit for the first three quarters, totaling 31.58 million yuan, with a revenue of 1.932 billion yuan, down 23.19% [4] - The third quarter revenue was 572 million yuan, a decline of 24.44% [4] Group 5 - WuXi AppTec plans to transfer 100% equity of two subsidiaries for a base price of 2.8 billion yuan, aiming to reinvest the funds into core business areas [5] - The sale of non-core assets is expected to enhance the company's competitiveness and potentially provide a short-term boost to stock prices [5]

Core Viewpoint - The company Shuyou Shen (300204) is undergoing a stock issuance process to raise funds for innovative drug research and to supplement working capital, amidst ongoing financial challenges and regulatory scrutiny [4][6][7]. Group 1: Stock Performance and Trading Information - As of October 24, 2025, Shuyou Shen's stock closed at 33.97 yuan, down 4.39%, with a turnover rate of 8.43% and a trading volume of 382,200 shares, amounting to a transaction value of 1.309 billion yuan [1]. - On the same day, the net outflow of main funds was 241 million yuan, while retail investors saw a net inflow of 250 million yuan [2]. Group 2: Financial Performance - For the fiscal year 2024, the company reported total assets of 1,149,607,757.17 yuan and total liabilities of 232,846,415.32 yuan, with a net profit of -147,731,291.05 yuan and a negative cash flow from operating activities of -63,682,894.36 yuan [3]. Group 3: Stock Issuance Details - The company plans to issue A-shares to specific investors, aiming to raise up to 1.253 billion yuan, with 883 million yuan allocated for innovative drug research and 370 million yuan for working capital [4][6]. - The issuance has been approved by the board and shareholders, but is pending review by the Shenzhen Stock Exchange and registration by the China Securities Regulatory Commission [5][7]. Group 4: Research and Development Focus - The company focuses on the development of innovative biopharmaceuticals targeting infectious diseases, respiratory and critical illnesses, autoimmune diseases, and neurological disorders, with several projects in advanced clinical trial stages [5][6].

Group 1: Company Performance Highlights - Ecovacs Robotics reported a significant increase in Q3 2025 revenue of 4.201 billion yuan, up 29.26% year-on-year, and a net profit of 438 million yuan, up 7160.87% [1] - Deep South Housing A achieved a revenue of approximately 898.85 million yuan in the first three quarters of 2025, a year-on-year increase of 331.66%, with a net profit of about 145.12 million yuan, up 2791.57% [1] - Antong Holdings reported Q3 2025 revenue of 2.152 billion yuan, an 18.85% increase year-on-year, and a net profit of 152 million yuan, up 2155.18% [2] - Sichuan Changhong's Q3 2025 revenue was 25.184 billion yuan, down 2.69% year-on-year, but net profit increased to 507 million yuan, up 690.83% [2] - Zhenghai Magnetic Materials reported a revenue of approximately 4.973 billion yuan for the first three quarters of 2025, a 30.54% increase, with a net profit of about 228 million yuan, up 20.46% [3] - Gold Mountain reported Q3 2025 revenue of 3.372 billion yuan, up 66.39% year-on-year, and a net profit of 951 million yuan, up 140.98% [4] Group 2: Corporate Actions and Strategic Moves - Yiyi Co. plans to acquire 100% equity of Gao Ye Jia, with the stock resuming trading on October 27 [6][8] - Ying Tang Zhi Kong is planning to issue shares to acquire assets, leading to a stock suspension starting October 27 [18][35] - Dream Jie Co. faced dissent from board member Chen Jie regarding the Q3 2025 report, raising concerns about its accuracy and completeness [9] - Drugmaker WuXi AppTec intends to sell 100% equity of two subsidiaries for 2.8 billion yuan to focus on its CRDMO business model [20][21] - Huayi Technology is planning to invest in a new project with a budget of approximately 266.65 million yuan for advanced manufacturing capabilities [22]

Core Viewpoint - Shuyou Shen (300204) has received acceptance from the Shenzhen Stock Exchange for its application to issue shares to specific investors, aiming to raise up to 1.253 billion yuan for innovative drug development and to supplement working capital [1][1][1] Group 1 - The company submitted its application for a private placement of shares on October 24 [1] - The Shenzhen Stock Exchange confirmed that the application documents were complete and decided to accept the application [1] - The intended fundraising amount is capped at 1.253 billion yuan [1]

Core Viewpoint - The company has received notification from the Shenzhen Stock Exchange regarding the acceptance of its application for a specific stock issuance, which is subject to further review and approval by regulatory authorities [1] Group 1: Company Actions - The company announced that on October 24, 2025, it received a notice from the Shenzhen Stock Exchange regarding the acceptance of its application for a specific stock issuance [1] - The application documents submitted by the company were found to be complete by the Shenzhen Stock Exchange, leading to the decision to accept the application [1] Group 2: Regulatory Process - The stock issuance is contingent upon approval from the Shenzhen Stock Exchange and the China Securities Regulatory Commission [1] - There is uncertainty regarding whether the application will pass the review by the Shenzhen Stock Exchange and receive the necessary registration approval from the China Securities Regulatory Commission [1] Group 3: Investor Communication - The company will fulfill its obligation to disclose information in a timely manner based on the progress of this matter [1] - Investors are advised to pay attention to investment risks associated with this process [1]

舒泰神10月26日公告，公司于2025年10月24日收到深交所出具的《关于受理舒泰神（北京）生物制药股 份有限公司向特定对象发行股票申请文件的通知》，深交所对公司报送的向特定对象发行股票的申请文 件进行了核对，认为申请文件齐备，决定予以受理。公司本次向特定对象发行股票事项尚需通过深交所 审核，并获得中国证监会作出的同意注册的决定后方可实施。 ...